Do-youn Dy Oh
#142,427
Most Influential Person Now
Do-youn Dy Oh's AcademicInfluence.com Rankings
Do-youn Dy Ohphilosophy Degrees
Philosophy
#7484
World Rank
#10705
Historical Rank
Logic
#4528
World Rank
#5837
Historical Rank
Download Badge
Philosophy
Do-youn Dy Oh's Degrees
- PhD Pharmaceutical Sciences University of California, San Francisco
- Doctorate Medicine Stanford University
Why Is Do-youn Dy Oh Influential?
(Suggest an Edit or Addition)Do-youn Dy Oh's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Trastuzumab emtansine for HER2-positive advanced breast cancer. (2012) (2725)
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial (2017) (1426)
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. (2019) (1152)
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study (2016) (864)
- Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. (2005) (783)
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. (2020) (629)
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. (2017) (443)
- Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial (2018) (402)
- HER2-targeted therapies — a role beyond breast cancer (2019) (387)
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. (2020) (355)
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. (2019) (308)
- A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. (2014) (252)
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies (2020) (215)
- Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis (2011) (209)
- Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index (2015) (182)
- Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). (2016) (153)
- First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors (2017) (152)
- Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer (2007) (150)
- Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer (2009) (145)
- Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma (2020) (139)
- The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer (2008) (131)
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. (2009) (129)
- A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data (2019) (129)
- Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. (2008) (127)
- Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells (2015) (124)
- The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. (2008) (122)
- KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach (2010) (122)
- APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. (2019) (115)
- Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. (2015) (115)
- RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib (2013) (114)
- Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2 (2009) (109)
- LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study (2020) (108)
- Aggressiveness of cancer-care near the end-of-life in Korea. (2008) (107)
- ATM in DNA repair in cancer. (2019) (106)
- OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. (2013) (102)
- Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation (2021) (101)
- Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. (2012) (101)
- Biliary tract cancer (2021) (100)
- Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors (2015) (97)
- Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. (2008) (91)
- Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment. (2008) (90)
- Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy (2016) (89)
- Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. (2022) (89)
- Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (2022) (86)
- Discrepancies among patients, family members, and physicians in Korea in terms of values regarding the withholding of treatment from patients with terminal malignancies (2004) (86)
- AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells (2017) (85)
- Ki-67 Expression Gives Additional Prognostic Information on St. Gallen 2007 and Adjuvant! Online Risk Categories in Early Breast Cancer (2009) (85)
- ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation (2019) (84)
- ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. (2007) (84)
- Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas (2012) (83)
- The role of PET/CT in detection of gastric cancer recurrence (2009) (82)
- Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing (2013) (79)
- Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells (2009) (78)
- Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker (2008) (77)
- Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer (2020) (74)
- Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment (2011) (74)
- Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy (2007) (74)
- Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. (2013) (73)
- Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study (2009) (73)
- CPR or DNR? End-of-life decision in Korean cancer patients: a single center’s experience (2006) (71)
- Pembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 study. (2018) (71)
- Antibiotic use during the last days of life in cancer patients. (2006) (71)
- Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC). (2019) (70)
- Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy (2011) (70)
- Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer (2011) (68)
- ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy (2014) (67)
- Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer (2011) (66)
- Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity. (2016) (66)
- Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review (2015) (65)
- The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy (2015) (62)
- A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy. (2016) (60)
- Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer (2007) (59)
- FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) (2019) (59)
- Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less (2010) (58)
- Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer (2015) (58)
- Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. (2009) (58)
- Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer (2021) (56)
- Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells (2008) (56)
- Increased fear of progression in cancer patients with recurrence. (2010) (56)
- Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer (2011) (56)
- Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review (2017) (55)
- Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer (2012) (55)
- Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations. (2019) (55)
- Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. (2009) (55)
- Role of adjuvant chemoradiotherapy for ampulla of Vater cancer. (2009) (55)
- Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. (2011) (53)
- Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial (2019) (53)
- Antitumor activity of NVP‐AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins (2011) (52)
- Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. (2021) (52)
- Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study (2008) (52)
- Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors (2017) (51)
- Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer (2010) (51)
- Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer (2013) (50)
- Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer. (2016) (50)
- Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy (2010) (50)
- Prognostic implication of antitumor immunity measured by the neutrophil–lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer (2017) (50)
- Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. (2019) (50)
- A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. (2008) (50)
- High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy. (2015) (49)
- KRAS Mutation is Associated with Worse Prognosis in Stage III or High-risk Stage II Colon Cancer Patients Treated with Adjuvant FOLFOX (2014) (49)
- Clinical Implications of VEGF, TGF-β1, and IL-1β in Patients with Advanced Non-small Cell Lung Cancer (2013) (49)
- Therapeutic implication of HER2 in advanced biliary tract cancer (2016) (48)
- Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. (2011) (47)
- The value of preoperative staging chest computed tomography to detect asymptomatic lung and liver metastasis in patients with primary breast carcinoma (2011) (47)
- Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. (2020) (46)
- A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. (2004) (46)
- Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer (2016) (46)
- Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells. (2018) (46)
- Weight changes after adjuvant treatment in Korean women with early breast cancer (2009) (45)
- Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy (2009) (45)
- Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy (2013) (45)
- Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach. (2018) (45)
- NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations (2011) (45)
- Heterodimerization of Glycosylated Insulin-Like Growth Factor-1 Receptors and Insulin Receptors in Cancer Cells Sensitive to Anti-IGF1R Antibody (2012) (44)
- RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase. (2010) (44)
- Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC). (2020) (44)
- Zinc-fingers and homeoboxes 1 (ZHX1) binds DNA methyltransferase (DNMT) 3B to enhance DNMT3B-mediated transcriptional repression. (2007) (43)
- Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer (2013) (43)
- Anti‐tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells (2017) (43)
- Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers (2012) (43)
- HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA). (2020) (43)
- Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation (2009) (42)
- The beneficial effect of palliative resection in metastatic colorectal cancer (2013) (42)
- Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition (2017) (41)
- Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer (2019) (41)
- Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy (2010) (41)
- Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab (2021) (40)
- Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer (2016) (39)
- A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer (2010) (39)
- [Breast cancer in the early stage]. (2012) (39)
- Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. (2022) (39)
- Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy (2011) (38)
- Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. (2019) (38)
- Metaplastic breast carcinoma: clinicopathologic features and prognostic value of triple negativity. (2010) (38)
- Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation. (2021) (38)
- Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: Which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study (2009) (37)
- Ataxia‐telangiectasia‐mutated protein expression with microsatellite instability in gastric cancer as prognostic marker (2014) (37)
- Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. (2006) (36)
- Clinicopathologic features and clinical outcomes of gastric cancer that initially presents with disseminated intravascular coagulation: A retrospective study (2010) (36)
- The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen. (2012) (35)
- Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases. (2013) (34)
- Public awareness of gastric cancer risk factors and disease screening in a high risk region: a population-based study. (2009) (34)
- Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary (2017) (33)
- Clinicopathologic Characteristics of Patients With Stage III/IV (M0) Advanced Gastric Cancer, According to HER2 Status Assessed by Immunohistochemistry and Fluorescence In Situ Hybridization (2011) (33)
- Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis (2011) (33)
- Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer. (2008) (33)
- Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study. (2021) (33)
- Adjuvant and Neoadjuvant Therapy for Gastric Cancer (2013) (33)
- Adjuvant Chemoradiotherapy After Curative Resection for Extrahepatic Bile Duct Cancer: A Long-term Single Center Experience (2012) (33)
- 1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer (2020) (32)
- Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival (2013) (31)
- Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitor. (2020) (31)
- Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer. (2006) (30)
- A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study. (2018) (30)
- Clinical Course of Neuroendocrine Tumors With Different Origins (the Pancreas, Gastrointestinal Tract, and Lung) (2012) (30)
- Phase II trial of dacomitinib in patients with HER2-positive gastric cancer (2016) (30)
- The influence of treatment response on the impact of resection margin status after preoperative chemoradiotherapy in rectal cancer. (2013) (30)
- A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma (2014) (30)
- Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary study (2016) (29)
- Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer (2019) (29)
- Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer (2019) (28)
- Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer (2016) (28)
- Optimal timing of influenza vaccination during 3‐week cytotoxic chemotherapy cycles (2017) (28)
- Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer (2012) (28)
- Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. (2009) (28)
- Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study. (2020) (27)
- Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. (2004) (27)
- Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy (2012) (27)
- Association between information provision and decisional conflict in cancer patients. (2015) (26)
- Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment (2016) (26)
- Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer. (2007) (26)
- Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations. (2018) (25)
- Long-Term Outcome of Distal Cholangiocarcinoma after Pancreaticoduodenectomy Followed by Adjuvant Chemoradiotherapy: A 15-Year Experience in a Single Institution (2016) (25)
- A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. (2019) (25)
- Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation (2013) (25)
- Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6 (2010) (25)
- High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer (2010) (24)
- Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI‐1 study (2019) (24)
- NTRK- and RET-fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. (2021) (24)
- A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer (2017) (23)
- Postoperative chemoradiotherapy for gallbladder cancer (2012) (23)
- Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer (2009) (23)
- Role of Adjuvant Chemoradiotherapy for Duodenal Cancer: A Single Center Experience (2012) (23)
- A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research (2009) (23)
- Outcome of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (iFAM) Chemotherapy and Analysis of Prognostic Factors in Patients with Refractory Advanced Biliary Tract Cancer (2012) (22)
- Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer (2007) (22)
- Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel (2017) (22)
- Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer (2005) (22)
- ABCB1, FCGR2A, and FCGR3A Polymorphisms in Patients with HER2-Positive Metastatic Breast Cancer Who Were Treated with First-Line Taxane plus Trastuzumab Chemotherapy (2012) (22)
- Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors (2015) (22)
- Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer (2010) (22)
- Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer (2019) (22)
- Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer (2013) (21)
- Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG) (2018) (21)
- A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearrangements (FOENIX-CCA3). (2020) (21)
- Impact of Multimodality Approach for Patients with Leptomeningeal Metastases from Solid Tumors (2014) (21)
- The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy. (2013) (21)
- Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer (2018) (20)
- Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia (2019) (20)
- DNA methyltransferase 3-like affects promoter methylation of thymine DNA glycosylase independently of DNMT1 and DNMT3B in cancer cells. (2010) (20)
- Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy (2009) (20)
- A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen. (2012) (19)
- A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. (2013) (19)
- Preliminary results of a ph2a study to evaluate the clinical efficacy and safety of erdafitinib in Asian patients with biomarker-selected advanced cholangiocarcinoma (CCA). (2018) (19)
- Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group (2019) (19)
- Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion. (2020) (19)
- Discrepancies in performance status scores as determined by cancer patients and oncologists: are they influenced by depression? (2007) (19)
- Artificial nutrition and hydration in terminal cancer patients: the real and the ideal (2007) (19)
- Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer (2012) (19)
- Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy (2019) (19)
- Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX (2015) (19)
- Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data (2012) (19)
- Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (2020) (18)
- Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy (2013) (18)
- Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells (2012) (18)
- Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy. (2018) (18)
- Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02) (2015) (18)
- Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021 (2020) (18)
- Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma (2015) (18)
- HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer (2013) (18)
- Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors (2017) (17)
- M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial. (2018) (17)
- MicroRNA-17 Acts as a Tumor Chemosensitizer by Targeting JAB1/CSN5 in Triple-Negative Breast Cancer. (2019) (17)
- Prognostic Factors Affecting the Outcome of Salvage Radiotherapy for Isolated Locoregional Recurrence After Mastectomy (2010) (17)
- POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm). (2016) (17)
- The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines (2012) (17)
- Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy (2017) (17)
- Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer (2022) (17)
- Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study (2019) (17)
- Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy (2014) (17)
- Cancer patients' awareness of clinical trials, perceptions on the benefit and willingness to participate: Korean perspectives (2008) (17)
- Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial. (2019) (16)
- Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer (2020) (16)
- TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials (2016) (16)
- Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma (2022) (16)
- Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer (2015) (16)
- A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09 (2015) (16)
- TGF-β Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells (2014) (16)
- A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer (2014) (16)
- Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma. (2018) (15)
- Metaplastic Breast Carcinoma: Clinicopathologic Features and Prognostic Value of Triple Negativity (2009) (15)
- Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis (2016) (15)
- Prognostic relevance of lymph node status for patients with ampullary adenocarcinoma after radical resection followed by adjuvant treatment. (2017) (15)
- Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer (2016) (15)
- More Accurate Prediction of Metastatic Pancreatic Cancer Patients’ Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity (2016) (15)
- Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer. (2005) (15)
- Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. (2021) (15)
- AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results (2019) (14)
- Evaluation of the willingness‐to‐pay for cancer treatment in Korean metastatic breast cancer patients: A multicenter, cross‐sectional study (2012) (14)
- Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer (2013) (14)
- Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer. (2005) (14)
- Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study. (2021) (14)
- Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study (2019) (14)
- Is There Any Role of Adjuvant Chemotherapy for T3N0M0 or T1N2M0 Gastric Cancer Patients in Stage II in the 7th TNM but Stage I in the 6th TNM System? (2016) (14)
- Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication (2017) (14)
- Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma (2012) (14)
- Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy. (2017) (14)
- Prognostic Value of p53 and bcl-2 Expression in Patients Treated with Breast Conservative Therapy (2007) (14)
- CD24 expression predicts distant metastasis in extrahepatic bile duct cancer. (2013) (13)
- Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours (2019) (13)
- P-cadherin expression in gastric carcinoma: its regulation mechanism and prognostic significance. (2010) (13)
- The impact of perioperative CA19‐9 change on the survival and recurrence patterns after adjuvant chemoradiotherapy in resectable extrahepatic cholangiocarcinoma (2018) (13)
- Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX (2016) (13)
- The prognostic role of soluble TGF‐beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy (2019) (13)
- Clinical Usefulness of AJCC Response Criteria for Neoadjuvant Chemotherapy in Breast Cancer (2013) (13)
- The influence of the treatment response on the impact of resection margin status after preoperative chemoradiotherapy in locally advanced rectal cancer (2013) (13)
- Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial. (2019) (12)
- Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I–III breast cancer patients (2019) (12)
- Korean Cancer Patients’ Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate (2017) (12)
- Age <40 Years is an Independent Prognostic Factor Predicting Inferior Overall Survival in Patients Treated with Breast Conservative Therapy (2011) (12)
- Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer (2015) (12)
- Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications (2016) (12)
- Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses (2016) (12)
- Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study (2015) (12)
- A-kinase anchoring protein 12 regulates the completion of cytokinesis. (2008) (12)
- Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications. (2015) (12)
- Pertuzumab in gastrointestinal cancer (2016) (11)
- Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer (2020) (11)
- Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy (2012) (11)
- Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer. (2017) (11)
- Capecitabine for the treatment of gastric cancer (2015) (11)
- Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. (2019) (11)
- Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202. (2021) (11)
- Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib/II study. (2021) (11)
- Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy (2019) (11)
- Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells (2018) (11)
- Clinical Outcomes of Sorafenib Treatment in Patients With Metastatic Hepatocellular Carcinoma Who Had Been Previously Treated With Fluoropyrimidine Plus Platinum-based Chemotherapy (2010) (11)
- DNA methyltransferase 3B acts as a co-repressor of the human polycomb protein hPc2 to repress fibroblast growth factor receptor 3 transcription. (2008) (11)
- Risk stratification and prognostic nomogram for post-recurrence overall survival in patients with recurrent extrahepatic cholangiocarcinoma. (2017) (11)
- Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress. (2020) (11)
- 5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study (2015) (10)
- Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis (2017) (10)
- Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy (2017) (10)
- A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1 (2019) (10)
- Src as a Therapeutic Target in Biliary Tract Cancer (2016) (9)
- Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients (2015) (9)
- Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy (2016) (9)
- The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer. (2015) (9)
- Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. (2008) (9)
- A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers. (2021) (9)
- Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection (2011) (9)
- Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology (2018) (9)
- DNA methyltransferase 3B mutant in ICF syndrome interacts non-covalently with SUMO-1 (2008) (9)
- Results from TreeTopp: A randomized phase II study of the efficacy and safety of varlitinib plus capecitabine versus placebo in second-line (2L) advanced or metastatic biliary tract cancer (BTC). (2020) (9)
- A Phase II study of 5-fluorouracil and cisplatin systemic chemotherapy for inoperable hepatocellular carcinoma with α fetoprotein as a predictive and prognostic marker. (2008) (9)
- Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies. (2019) (9)
- Abstract CT111: Avelumab (anti-PD-L1) as first-line maintenance (1L mn) or second-line (2L) therapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated phase Ib results from the JAVELIN Solid Tumor trial (2018) (9)
- Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma. (2010) (8)
- Adjuvant Chemotherapy in Microsatellite Instability–High Gastric Cancer (2020) (8)
- Postoperative chemoradiotherapy in high risk locally advanced gastric cancer (2012) (8)
- AB053. P-21. M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): efficacy by BTC subtype (2019) (8)
- Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer (2011) (8)
- MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers. (2019) (8)
- Prospective evaluation of changes in tumor size and tumor metabolism in advanced gastric cancer undergoing chemotherapy: association and clinical implication (2016) (8)
- Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC). (2018) (8)
- Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients (2019) (8)
- A phase I, open-label, nonrandomized trial of OPB-31121, a STAT3 inhibitor, in patients with advanced solid tumors. (2010) (8)
- A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer (2008) (8)
- Nomogram prediction of survival and recurrence in patients with extrahepatic bile duct cancer undergoing curative resection followed by adjuvant chemoradiation therapy. (2013) (8)
- Is duodenal invasion a relevant prognosticator in patients undergoing adjuvant chemoradiotherapy for distal common bile duct cancer? (2010) (8)
- Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer (2022) (8)
- M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype. (2018) (8)
- Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. (2014) (8)
- Vandetanib plus mFOLFOX6 in patients with advanced colorectal cancer (CRC): A randomized, double-blind, placebo-controlled phase II study. (2016) (8)
- A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo (2017) (8)
- Chemotherapy-induced transient CEA and CA19–9 surges in patients with metastatic or recurrent gastric cancer (2008) (8)
- Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: second interim overall survival (OS) results from the RADIANT-4 Study. (2016) (8)
- Efficacy of reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer (CRC) (2005) (8)
- Overexpression of A-kinase anchoring protein 12A activates sterol regulatory element binding protein-2 and enhances cholesterol efflux in hepatic cells. (2008) (7)
- Perceived needs for the information communication technology (ICT)‐based personalized health management program, and its association with information provision, health‐related quality of life (HRQOL), and decisional conflict in cancer patients (2017) (7)
- Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. (2022) (7)
- Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells. (2012) (7)
- FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. (2019) (7)
- Distant metastasis risk stratification for patients undergoing curative resection followed by adjuvant chemoradiation for extrahepatic bile duct cancer. (2012) (7)
- GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer (2019) (7)
- Prognostic implication of 18F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study (2011) (7)
- Avelumab (MSB0010718C), an anti-PD-L1 antibody, as a third-line treatment in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib JAVELIN Solid Tumor trial. (2016) (7)
- Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies. (2018) (7)
- Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment. (2017) (7)
- The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use. (2012) (7)
- A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma (2018) (7)
- MORPHEUS: A phase Ib/II multi-trial platform evaluating the efficacy and safety of cancer immunotherapy (CIT)-based combinations in patients (pts) with gastric or pancreatic cancer. (2018) (7)
- Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy (2017) (7)
- The comparison of the benefits obtained from platinum-containing chemotherapy between triple-negative and non-triple-negative metastatic breast cancer. (2010) (7)
- Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors. (2015) (7)
- WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers (2021) (7)
- ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer. (2021) (7)
- Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial (2019) (6)
- A phase I study of HM781-36B, a novel pan-HER inhibitor, in patients (pts) with advanced solid tumors. (2012) (6)
- Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting (2011) (6)
- Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer. (2008) (6)
- Prognostic Value of Splenic Artery Invasion in Patients Undergoing Adjuvant Chemoradiotherapy after Distal Pancreatectomy for Pancreatic Adenocarcinoma (2014) (6)
- Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial. (2016) (6)
- Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion (2020) (6)
- Comparisons of Clinical Outcomes between Weekday-Only and Full-Time, 24-Hour/7-Day Coverage Hospitalist Systems (2020) (6)
- Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study (2021) (6)
- CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy (2017) (6)
- Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors. (2020) (6)
- Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX (2020) (6)
- A phase III, multicenter, randomized trial of maintenance versus observation after achieving clinical response in patients with metastatic breast cancer who received six cycles of gemcitabine plus paclitaxel as first-line chemotherapy (KCSG-BR 0702, NCT00561119). (2012) (6)
- The Prognostic Importance of the Number of Metastatic Lymph Nodes for Patients Undergoing Curative Resection Followed by Adjuvant Chemoradiotherapy for Extrahepatic Bile Duct Cancer (2015) (6)
- Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03. (2022) (6)
- 17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy. (2011) (5)
- Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis (2019) (5)
- Abstract P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study (2022) (5)
- Salvage radiotherapy for locoregionally recurrent extrahepatic bile duct cancer after radical surgery. (2017) (5)
- Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy (2021) (5)
- Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial. (2019) (5)
- MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer. (2018) (5)
- Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer (2020) (5)
- Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer (2018) (5)
- Prospective Evaluation of the Clinical Implications of the Tumor Metabolism and Chemotherapy-Related Changes in Advanced Biliary Tract Cancer (2017) (5)
- Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer. (2005) (5)
- Baseline demographics of the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET). (2015) (5)
- Does adjuvant radiotherapy suppress liver regeneration after partial hepatectomy? (2009) (5)
- Role of Adjuvant Chemoradiotherapy for Duodenal Cancer: An Updated Analysis of Long-Term Follow-Up from Single Institution (2018) (5)
- Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer (2016) (5)
- Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients (2020) (5)
- Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4 (2017) (5)
- The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. (2010) (5)
- Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer. (2011) (5)
- 73P Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer (2020) (4)
- Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients (2019) (4)
- TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy (2020) (4)
- Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy (2013) (4)
- Evaluation of minimal important difference (MID) for the European organisation for research and treatment of cancer (EORTC) pancreatic cancer module (PAN26) in patients with surgically resected pancreatic adenocarcinoma (2019) (4)
- Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp) (2021) (4)
- AB062. P-33. Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: a pooled analysis from three phase 1 studies (2019) (4)
- Chemoradiotherapy for extrahepatic bile duct cancer with gross residual disease after surgery. (2011) (4)
- VEGF Expression is Related to Good Response and Long Progression-free Survival in Gastrointestinal Stromal Tumor Patients Treated With Sunitinib (2011) (4)
- 2364 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib trial (2015) (4)
- TREETOPP: A phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs). (2018) (4)
- Abstract A167: A phase I study of MET TKI SAR125844 in Asian patients (pts) with advanced solid tumors (2015) (4)
- Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study (2019) (4)
- Increasing nodal ratio is a poor prognostic factor for survival in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study. (2011) (4)
- Chemoradiotherapy after gemcitabine plus erlotinib in patients with locally advanced pancreatic cancer. (2017) (4)
- Prognostic effects of abnormal DNA damage response protein expression in breast cancer (2019) (4)
- Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors (2013) (4)
- Phase II study and biomarker analysis of cetuximab in combination with oxaliplatin, 5-fluorouracil, leucovorin as first-line treatment in patients with recurrent or metastatic gastric cancer (2008) (4)
- The impact of diabetes mellitus and metformin on survival of patients with advanced pancreatic cancer receiving chemotherapy. (2013) (4)
- Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC). (2020) (3)
- The TRAR gene classifier to predict response to neoadjuvant therapy in HER2‐positive and ER‐positive breast cancer patients: an explorative analysis from the NeoSphere trial (2021) (3)
- Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer (2021) (3)
- Acute myelogenous Leukemia in the elderly ($\geq$60): retrospective study of 115 patients (2006) (3)
- A phase 2, open-label, multicenter study of durvalumab (MEDI4736) ± tremelimumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS. (2016) (3)
- Phase II trial of postoperative adjuvant gemcitabine and cisplatin chemotherapy followed by chemoradiation with gemcitabine in patients with resected pancreatic cancer. (2011) (3)
- Efficacy of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer. (2001) (3)
- Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC). (2020) (3)
- Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach. (2018) (3)
- A phase IB study of CX-4945 in combination with gemcitabine plus cisplatin in the frontline systemic treatment of patients with advanced cholangiocarcinoma. (2017) (3)
- A First‐in‐Human Phase I Study of GC1118, a Novel Anti‐Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors (2019) (3)
- Prognostic value of serum soluble programmed death-ligand 1 (sPDL1) and dynamics during chemotherapy in advanced gastric cancer patients. (2019) (3)
- 79TiP A phase II/III, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer (2020) (3)
- Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer (2014) (3)
- Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer (2011) (3)
- High expression of MMP-9 is associated with better prognosis in extrahepatic bile duct cancer patients. (2018) (3)
- Prognostic Significance of Nodal Ratio in Patients Undergoing Adjuvant Chemoradiotherapy After Curative Resection for Ampullary Cancer (2016) (3)
- Myocardial Metastasis in Patient with Cholangiocarcinoma (2009) (3)
- Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. (2022) (3)
- Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study. (2021) (3)
- Phase II study of low-dose paclitaxel and cisplatin as second-line therapy in 5-fluorouracil and platinum pretreated gastric cancer (2005) (2)
- The role of adjuvant chemoradiotherapy in non-hilar extrahepatic bile duct cancer: A long term single institutional analysis. (2021) (2)
- Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial (2022) (2)
- Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16) (2022) (2)
- PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement. (2022) (2)
- EGFR mutation and intron 1 CA repeat polymorphism as predictive markers of gefitinib responsiveness in non-small cell lung cancer (NSCLC). (2006) (2)
- A case of primary breast synovial sarcoma diagnosed in a young female patient (2010) (2)
- Comparison of concurrent chemoradiotherapy and chemotherapy alone for locally advanced pancreatic cancer. (2014) (2)
- Antibodies that Inhibit Specific Cellular Pathways in Gastric Cancer (2017) (2)
- Chemical Therapeutics RAD 51 CDe fi cient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib (2013) (2)
- AB052. P-20. Phase 2, open-label study of second-line M7824 treatment in patients with locally advanced or metastatic biliary tract cancer (2019) (2)
- Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in previously treated advanced hepatocellular carcinoma. (2012) (2)
- Safety and efficacy of everolimus in advanced nonfunctional Neuroendocrine Tumors (NET) of lung or Gastrointestinal (GI) origin: findings of the randomized, placebo-controlled, double-blind, multicenter, phase 3 RADIANT-4 study (2016) (2)
- Phase Ib study of binimetinib (MEK162) in combination with capecitabine in gemcitabine-pretreated advanced biliary tract cancer. (2018) (2)
- Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study. (2022) (2)
- Abstract B001: Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer (2019) (2)
- Evaluation of pembrolizumab monotherapy in patients with salivary gland carcinoma in the phase 2 KEYNOTE-158 study (2021) (2)
- Magnitude of HER2 amplification as a predictive factor for HER2-overexpressing metastatic breast cancer treated with weekly paclitaxel plus trastuzumab as first-line chemotherapy (2008) (2)
- Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma (2021) (2)
- The prognostic role of soluble transforming growth factor-β related with soluble programmed death-ligand 1 in biliary tract cancer. (2019) (2)
- Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC). (2022) (2)
- A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors. (2021) (2)
- A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations (2021) (2)
- The prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer (2020) (2)
- Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced gastric and gastroesophageal junction adenocarcinoma (SGNLVA-005, Trial-in-Progress). (2021) (2)
- Which is better in patients with curatively resected extrahepatic biliary tract cancer? Adjuvant concurrent chemoradiation (CCRT) alone versus CCRT followed by maintenance chemotherapy (2008) (2)
- Abstract CT201: Phase Ib/II open-label, randomized evaluation of atezolizumab + cobimetinib vs control in MORPHEUS-NSCLC (non-small cell lung cancer), MORPHEUS-PDAC (pancreatic ductal adenocarcinoma) and MORPHEUS-GC (gastric cancer) (2020) (2)
- Quantitative measurement of HER2 levels by multiplexed mass spectrometry to predict survival in gastric cancer patients treated with trastuzumab. (2015) (2)
- Phase I study of BI 754091 plus BI 754111 in Asian patients with gastric/gastroesophageal junction or esophageal cancer. (2021) (2)
- Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial. (2020) (2)
- A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers (2021) (2)
- Abstract P6-18-11: Long-term responders to single-agent margetuximab, an Fc-modified anti-HER2 monoclonal antibody, in metastatic HER2+ breast cancer patients with prior anti-HER2 therapy (2019) (2)
- P-144 Infigratinib versus gemcitabine plus cisplatin as first-line therapy in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: phase 3 PROOF trial (2020) (2)
- 134ORADIANT-4: Efficacy and safety of everolimus in advanced, nonfunctional neuroendocrine tumors (NET) of the lung or gastrointestinal (GI) tract (2015) (2)
- Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC). (2012) (2)
- 284P Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): Data from the phase III EMILIA study (2021) (1)
- Treatment for unresectable gastric cancer (2015) (1)
- First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors. (2022) (1)
- Evaluation of Xerostomia Following 3 Dimensional Conformal Radiotherapy for Nasopharyngeal Cancer Patients. (2006) (1)
- SO-3 Maintenance olaparib in patients aged ≥65 years with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial (2020) (1)
- Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma. (2020) (1)
- Phase II Trial of Vinorelbine and Cisplatin Chemotherapy in Advanced Non-Small Cell Lung Cancer. (2001) (1)
- Abstract P1-10-11: Prognostic value of non-alcoholic fatty liver disease in stage II/III breast cancer patients who received neoadjuvant chemotherapy (2016) (1)
- P5-5 Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer (2021) (1)
- Residual disease after HER2-directed therapies in the neosphere study: Modulation of tumor lymphocyte infiltration (TIL) and prognosis. (2016) (1)
- Multicenter retrospective analysis for efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU/leucovorin (5-FU/LV) after progression on gemcitabine-based therapy in Korean patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A study by Korean Cancer Study Group (KCSG). (2019) (1)
- 1014TiP PROOF: A multicenter, open-label, randomized, phase III trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with FGFR2 gene rearrangements (2020) (1)
- Impact of radiation dose in postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: long term results from a single institution. (2017) (1)
- Role of adjuvant chemoradiotherapy for duodenal cancer: An update of the experience at a single institution. (2016) (1)
- Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study (2019) (1)
- Immunogenicity and Safety of Influenza Vaccination in Cancer Patients Receiving Immune Checkpoint Inhibitor (2019) (1)
- Phase III study of NUC-1031 + cisplatin versus gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121). (2021) (1)
- 439P Phase Ib/II study of ibrutinib (ibr) in combination with cetuximab (cetux) in patients (pts) with previously treated metastatic colorectal cancer (mCRC) (2020) (1)
- POLO: Health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer (mPC) (2019) (1)
- Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16) (2021) (1)
- Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I–III breast cancer patients (2019) (1)
- Abstract 1714: The role and mechanism of JAB1 as a therapeutic target in biliary tract cancer (2015) (1)
- The role of soluble TGF-beta and its dynamics for predicting the prognosis in unresectable pancreatic cancer patients treated with chemotherapy. (2018) (1)
- Abstract 1775: Growth inhibitory effect of PARP inhibitor olaparib in gastric cancer cells (2010) (1)
- Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer (2020) (1)
- Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study. (2023) (1)
- A New Isolated Mediastinal Lymph Node or Small Pulmonary Nodule Arising during Breast Cancer Surveillance Following Curative Surgery: Clinical Factors That Differentiate Malignant from Benign Lesions (2014) (1)
- Impact of adjuvant treatment with nab-paclitaxel and gemcitabine (nab-P+GEM) vs gemcitabine alone (GEM) on health-related quality of life (QoL) in patients (pts) with surgically resected pancreatic adenocarcinoma (PA) in the adjuvant pancreatic adenocarcinoma clinical trial (APACT) (2019) (1)
- An Analysis of Treatment Results of Lymphoblastic Lymphoma in Adults According to the Chemotherapy Regimens (2003) (1)
- Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial. (2020) (1)
- 3509 POSTER Growth inhibitory effects and mechanisms of lapatinib, a dual inhibitor of ErbB1 and ErbB2 tyrosine kinase, in gastric cell lines (2007) (1)
- POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC) (2019) (1)
- Results of breast‐conserving therapy for multifocal or multicentric breast cancers (2009) (1)
- Correction: Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel (2018) (1)
- Chemical Therapeutics Discovery & Preclinical Development Antitumor Activity of Saracatinib ( AZD 0530 ) , a cSrc / Abl Kinase Inhibitor , Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer (2013) (1)
- Clinicopathologic characteristics of microsatellite instability (MSI) tumors in resected gastric cancer patients. (2010) (1)
- Usefulness of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy to predict prognosis of advanced biliary tract cancer. (2017) (1)
- Weight loss at the first month of palliative chemotherapy to predict survival outcomes in patients with advanced gastric cancer. (2015) (1)
- The Impact of Primary Tumor Resection on the Survival of Patients with Stage IV Breast Cancer (2010) (1)
- The Results of Postoperative Radiotherapy for Early Stage Endometrial Carcinoma. (2006) (1)
- 1527P Assessing clinical benefit of olaparib maintenance treatment in subgroups of patients with germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer: Phase III POLO trial (2020) (1)
- HALO 110-101: A phase Ib, randomized, open-label study of PEGPH20 (pegvorhyaluronidase alfa) in combination with cisplatin (CIS) + gemcitabine (GEM) (PEGCISGEM) or atezolizumab and CIS + GEM (PEGCISGEMATEZO) in hyaluronan-high subjects with locally advanced or metastatic cholangiocarcinoma and gallb (2018) (1)
- HER2, p95HER2, and HER3 expression and treatment outcome of lapatinib plus capecitabine in HER2-positive, trastuzumab-refractory metastatic breast cancer. (2010) (1)
- Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P). (2020) (1)
- Silmitasertib plus gemcitabine and cisplatin first‐line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study (2022) (1)
- Abstract 747: Evaluation of Src as a therapeutic target and development of biomarkers of Src inhibitor in cancer (2014) (1)
- Molecular characteristics and prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX. (2013) (1)
- A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naïve, advanced, or metastatic biliary tract cancer (BTC). (2019) (1)
- Effect of Suboptimal Chemotherapy on Preoperative Chemoradiation in Rectal Cancer (2009) (1)
- Image Gallery: Squamous cell carcinoma on an untreated vitiligo lesion (2018) (1)
- An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors. (2020) (1)
- Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation. (1)
- POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC). (2020) (1)
- Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea (2016) (1)
- Abstract LB-107: Targeting ATR using a novel ATR inhibitor AZD6738 in human gastric cancer cells (2015) (1)
- ISY-12-4Efficacy and Safety of Everolimus in Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: Findings From the Asian Subgroup Analysis of the RADIANT-4 Study (2016) (1)
- AB040. P-08. FOENIX-CCA2: a phase 2 study of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements (2019) (1)
- Abstract 3496: GC1118, a novel anti-EGFR andtibody, shows more potent antitumor activity regardless of KRAS mutation or high-affinity lignad stimulation compared with cetuximab in gastric cancer (2018) (1)
- Phosphorylated Akt Expression as a Favorable Prognostic Factor for Patients Undergoing Curative Resection and Adjuvant Chemoradiotherapy for Proximal Extrahepatic Bile Duct Cancer (2017) (1)
- A first-in-human phase 1 study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with advanced solid tumors. (2016) (1)
- Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish). (2023) (1)
- New approach for assessment of potential ethnic differences in parallel phase l/ll studies in the United States and Asia. (2010) (1)
- Postoperative Adjuvant Chemoradiotherapy in Rectal Cancer. (2006) (1)
- Preclinical Development Evaluation of the Antitumor Effects and Mechanisms of PF 00299804 , a Pan-HER Inhibitor , Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer (2012) (1)
- Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress). (2021) (1)
- Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16). (2021) (1)
- Role of adjuvant radiotherapy in extrahepatic bile duct cancer: A multicenter retrospective study (Korean Radiation Oncology Group 18-14). (2021) (1)
- TTP or PFS as a surrogate endpoint in advanced hepatocellular carcinoma treated with systemic therapy. (2016) (1)
- DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: A phase 2 trial-in-progress. (2021) (1)
- Lapatinib can restore capecitabine sensitivity in HER2-positive breast cancer. (2009) (1)
- Impact of radiation dose in postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: long term results from a single institution (2017) (1)
- Measurement of soluble Programmed Death-Ligand 1 (soluble PD-L1) to predict survival in biliary tract cancer patients treated with chemotherapy. (2015) (1)
- Skeletal muscle depletion to predict survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy. (2017) (1)
- Korean Cancer Patients’ Awareness of Clinical Trials: Perceptions on the benefit and willingness to participate. (2016) (1)
- Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy (2021) (1)
- Abstract B260: Antitumor activity of HM781‐36B, an irreversible pan‐HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer cells (2009) (0)
- Abstract 2427: Overexpression of insulin/IGF hybrid receptor as predictive biomarker of response to a humanized anti-insulin like growth factor-I receptor monoclonal antibody (CP751,871) in gastric and hepatocellular carcinoma cells (2010) (0)
- 190P Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC) (2020) (0)
- Prognostic role of PIK3CA mutational status in cell free DNA (cfDNA) from HER2-positive metastatic breast cancer patients (2017) (0)
- Dynamics of soluble programmed death-ligand 1 (soluble PDL1) during chemotherapy and its prognostic implication in cancer patients. (2017) (0)
- Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers (2013) (0)
- Ki-67 gives additional prognostic information on St Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. (2009) (0)
- Abstract 4931: Validation of Trastuzumab immunohistochemistry as a predictive and prognostic biomarker in gastric cancer patients (2016) (0)
- 6573 The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer (2009) (0)
- ABCB1 polymorphism as a prognostic factor in breast cancer patients with neoadjuvant chemotherapy. (2014) (0)
- Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients (2015) (0)
- Abstract CT098: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced IDH-mutant cholangiocarcinoma and other solid tumors (2023) (0)
- Biomarkers to predict sensitivity to HER2-targeting treatment in HER2-positive advanced gastric cancer. (2014) (0)
- Correlation of loss of ataxia-telangiectasia-mutated protein expression with poor prognosis and benefit from anthracycline containing adjuvant chemotherapy in breast cancer. (2016) (0)
- Phase II Trial of TS-1 in Combination with Oxaliplatin (SOX) in Patients with Metastatic Breast Cancer (MBC) Previously Treated with Anthracycline and Taxane Chemotherapy [TORCH] [Korean Cancer Study Group (KCSG) BR07-03] (2012) (0)
- Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers. (2023) (0)
- IS3. Gastric Cancer (2012) (0)
- P-181Outcome Analysis of Upfront Definitive Chemoradiation for Unresectable Pancreatic Adenocarcinoma: A Single Center Experience for over 25 years (2015) (0)
- Abstract 3940: Baseline molecular markers and risk of distant relapse in the NeoSphere study (2016) (0)
- 409 Trial in progress: a phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer (2021) (0)
- Health-related quality of life (HRQoL) in patients with early-stage pancreatic cancer (ESPC) receiving adjuvant or neoadjuvant chemotherapy (A/NAC): A systematic literature review (SLR). (2018) (0)
- Metabolic landscape using 18F-FDG PET and its clinical significances in advanced biliary tract cancer. (2014) (0)
- AB063. P-34. A multicenter, phase 1b/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment naïve advanced or metastatic biliary tract cancer (BTC) (2019) (0)
- Novel biomarker panel for the early detection of pancreatic cancer and its clinical validation (2016) (0)
- AOS10 Prognostic factors for patients with leptomeningeal metastases from solid tumours (2012) (0)
- A first-in-human phase I study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with colorectal cancer and gastric/GEJ cancer. (2018) (0)
- Adjuvant Radiotherapy after Surgical Resection for Gallbladder Cancer (2009) (0)
- Interim analysis of first-in-human phase 1 study to assess safety and efficacy of YBL-006, an anti-PD-1 antibody in advanced solid tumor with exploratory biomarker analysis of tumor mutational burden and artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes. (2021) (0)
- MO31-6 Maintenance olaparib in Asian patients with germline BRCA-mutated metastatic pancreatic cancer (2021) (0)
- 715PJab1 silencing inhibits proliferation and sensitizes to cisplatin in biliary tract cancer (2017) (0)
- Abstract 3872: Targeting of YAP overcomes trastuzumab-resistance and promotes immune responses in HER2-positive cancers (2023) (0)
- 658 A phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer (2022) (0)
- Abstract 5334: Targeting the hippo transducer YAP overcomes trastuzumab-resistance in HER2-positive cancers (2022) (0)
- P310 Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy (2011) (0)
- ' s response to reviews Title : Prognostic impact of clinicopathologic parameters in stage II / III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy : paradoxical features of the triple negative breast cancer (2007) (0)
- HALO 109-301: Phase III, randomized, double-blind, placebo-controlled study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients with previously untreated hyaluronan (HA)-high stage IV pancreatic ductal adenocarcinoma (PDA). (2018) (0)
- Morpheus (2020) (0)
- Management (mgmt) of futibatinib-associated adverse events (AEs) in patients (pts) with advanced cancers: Results of a pooled analysis. (2023) (0)
- PR99 QUALITY OF LIFE (QOL) IN METASTATIC BREAST CANCER PATIENTS WITH MAINTENANCE PACLITAXEL PLUS GEMCITABINE (PG) CHEMOTHERAPY: RESULTS FROM PHASE III, MULTICENTER, RANDOMIZED TRIAL OF MAINTENANCE CHEMOTHERAPY VERSUS OBSERVATION (KCSG-BR07-02) (2013) (0)
- Abstract 323: DNA damage response (DDR)-targeting strategy by targeting WEE1 and or ATM/ATR works in biliary tract cancer (2018) (0)
- Genetic polymorphisms and ethnic difference in outcome of adjuvant FOLFOX chemotherapy in Korean patients with colon cancer. (2012) (0)
- Abstract 1421: Evaluation of DDR-targeting strategy using ATR inhibitor in biliary tract cancer (2017) (0)
- Abstract 2975: Rad21, as a high order chromatin architecture molecule, regulates global gene transcription. (2013) (0)
- Abstract C16: Prospective real‐time analysis of p‐cadherin expression to select patients into a phase I oncology trial (2009) (0)
- 713P The mutational landscape of periampullary adenocarcinomas in relation to morphological subtype and patient survival (2017) (0)
- ' s response to reviews Title : Prognostic impact of clinicopathologic parameters in stage II / III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy : paradoxical features of the triple negative breast cancer (2007) (0)
- Halo 110-101: Early safety results of pegvorhyaluronidase alfa (PEGPH20; PVHA) + cisplatin (C) + gemcitabine (G) ± atezolizumab (ATZ) in patients (pts) with locally advanced or metastatic cholangiocarcinoma (CCA) and gallbladder cancer (GBC). (2019) (0)
- Abstract 331: Therapeutic co-targeting of WEE1 and ATM has synergistic effects and contributes to downregulation of PD-L1 expression in pancreatic cancer (2018) (0)
- Single Nucleotide Polymorphism (SNP) in RASSF1 and Clinical Outcomes of Breast Cancer Patients Treated with Neoadjuvant Docetaxel/Doxorubicin Chemotherapy. (2009) (0)
- PSY7-5 Current status and future perspectives in biliary tract cancer in Korea (2021) (0)
- P3-16-06: Phase II Trial of TS-1 in Combination with Oxaliplatin (SOX) in Patients with Metastatic Breast Cancer (MBC) Previously Treated with Anthracycline and Taxane Chemotherapy [TORCH] [Korean Cancer Study Group (KCSG) BR07-03]. (2011) (0)
- Novel biomarker panel for the early detection of pancreatic cancer using peripheral blood (2016) (0)
- P-189 Trimodality therapy for mediastnoscopic N2-positive non-smallcell lung cancer (2005) (0)
- Predictive role of temporal changes in intratumoral metabolic heterogeneity during palliative chemotherapy in advanced pancreatic cancer patients: A prospective cohort study. (2019) (0)
- The influence of the treatment response on the impact of resection margin status after preoperative chemoradiotherapy in locally advanced rectal cancer (2013) (0)
- Abstract P2-09-36: Role of ABCB1 Polymorphisms as Predictive Markers in Patients with HER-2 FISH Positive Metastatic Breast Cancer Who Were Treated with Taxane Plus Trastuzumab First Line Chemotherapy (2010) (0)
- Phosphorylated Akt expression as a favorable prognostic factor for patients undergoing curative resection and adjuvant chemoradiotherapy for proximal extrahepatic bile duct cancer. (2013) (0)
- A target‐mediated drug disposition population pharmacokinetic model of GC1118, a novel anti‐EGFR antibody, in patients with solid tumors (2020) (0)
- Combination of chemotherapy and focused ultrasound for the treatment of unresectable pancreatic cancer: a proof-of-concept study (2022) (0)
- Phase II study of neoadjuvant chemotherapy with paclitaxel and cisplatin in Stage IIIA N2 non-small cell lung cancer (2004) (0)
- Abstract A252: KRAS mutant lung cancer cells are differentially responsive to MEK inhibition due to AKT or STAT3 activation: Implication for combinatorial approach (2009) (0)
- Prediction of metastatic pancreatic cancer patients’ survival using both host immunity and tumor metabolic activity. (2016) (0)
- Abstract P3-11-15: Different clinical usefulness of AJCC response criteria according to the subtypes in stage II/III breast cancer patients after neoadjuvant chemotherapy (2015) (0)
- Abstract P3-12-07: A multicenter randomized double-blind phase III clinical trial to evaluate the efficacy and safety of GCPGC, a novel pegylated G-CSF in patients receiving DA or TAC chemotherapy for breast cancer compared to peg-filgrastim (2015) (0)
- P-190 Prognostic factors of N2 positive stage IIIA non-small cell lung cancer treated with preoperative concurrent radiochemotherapy and surgery (2005) (0)
- Abstract 5869: Resistance mechanism against trastuzumab in HER2-positive cancer cells and its negation by Src inhibition (2017) (0)
- 551 POSTER Clinical significance of MDR1/ABCB1 single nucleotide polymorphism (SNP) in the breast cancer patients receiving neoadjuvant chemotherapy (2007) (0)
- A phase II study of nab-paclitaxel and gemcitabine in Korean patients with metastatic pancreatic cancer. (2018) (0)
- Abstract 3588: Antitumor activity of saracatinib, a c-Src/Abl kinase inhibitor, in gastric cancer (2011) (0)
- The prognostic role of soluble transforming growth factor-β (sTGFb) and soluble programmed death-ligand 1 (sPDL1) in biliary tract cancer patients treated with binimetinib and capecitabine. (2019) (0)
- Abstract LB-107: Androgen receptor inhibitor enhances the antitumor effect of PARP inhibitor in breast cancer cells via modulation of DNA damage response (2016) (0)
- 6544 The clinicopathologic features and clinical outcomes of gastric cancer initially presented with disseminated intravascular coagulopathy (2009) (0)
- A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer (2015) (0)
- Abstract 4739: Prognostic impact of abnormal DNA damage response protein expression in breast cancer (2017) (0)
- A randomized, multi-center phase III trial of adjuvant chemotherapy with gemcitabine and capecitabine (GemCap) compared to capecitabine (Cap) alone in curatively resected biliary tract cancer (BilGemCap Study): KCSG HB20-14. (2023) (0)
- 2274 Is there any role of adjuvant chemotherapy for T3N0M0 or T1N2M0 gastric cancer, stage II in 7th TNM but stage I in 6th TNM system? (2015) (0)
- Metabolic landscape and prognostic value of HER2 in advanced gastric cancer. (2014) (0)
- Abstract 2422: Pan-pim kinases inhibitor, AZD1208 suppresses tumor growth and synergistically interacts with an AKT inhibitor in gastric cancer cells (2015) (0)
- Patterns of Failure After Adjuvant Radiation Therapy Based on Tumor Bed With Margin for Stage II-IV Thymic Carcinoma (2017) (0)
- Abstract P4-07-08: The prognostic significance of ataxia-telangiectasia-mutated (ATM) and p53 expression in breast cancer (2016) (0)
- 2100 The role of 18F-FDG PET in detection of biliary tract cancer recurrence during surveillance: A single center observational study (2009) (0)
- Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma. (2023) (0)
- Abstract 4496: JPI-547, a dual inhibitor of PARP/Tankyrase, shows promising antitumor activity against pancreatic cancers with homologous recombination repair deficiency or Wnt-addiction (2023) (0)
- Abstract P4-16-06: Histone deacetylases inhibitor SAHA enhances anti-tumor effects of poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in breast cancer cells (2013) (0)
- Prognostic Factors for Patients With Leptomeningeal Metastases From Solid Tumor (2012) (0)
- 5042 POSTER Clinical Implications of Palliative Surgery in Patients With Suspicious Versus Proven Metastatic Breast Cancer Under Current Staging System (2011) (0)
- Prospective evaluation of metabolic intratumoral heterogeneity using 18F-FDG-PET-CT in patients with advanced gastric cancer receiving palliative chemotherapy. (2019) (0)
- Abstract CT257: First-in-human phase 1 studies of PTPN2/1 inhibitors ABBV-CLS-484 and ABBV-CLS-579 in locally advanced or metastatic tumors (2023) (0)
- Prognostic Factors for Patients With Leptomeningeal Metastases From Solid Tumor (2012) (0)
- Health-related quality of life in patients treated with gemcitabine/cisplatin and durvalumab ± tremelimumab in chemotherapy-naïve advanced biliary tract cancer. (2022) (0)
- Risk Stratification of Distant Metastasis in Patients Undergoing Adjuvant Chemoradiation for Extrahepatic Bile Duct Cancer (2010) (0)
- Kaplan-Meier analyses of survival according to clinical and pathologic stages (2011) (0)
- CTX-009 (ABL001), a bispecific antibody targeting DLL4 and VEGF A, in combination with paclitaxel in patients with advanced biliary tract cancer (BTC): A phase 2 study. (2023) (0)
- Analysis of the role of tumor microenvironment on clinical outcomes of chemotherapy in patients with advanced gastric cancer using high plex digital spatial profiling. (2023) (0)
- Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer. (2023) (0)
- Surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: Meta-analysis of randomized controlled trials. (2017) (0)
- Biomarker-oriented study of pembrolizumab in combination with chemotherapy in chemotherapy-naïve advanced pancreatic cancer: A phase 2 trial-in-progress. (2022) (0)
- Abstract 3599: Resistance mechanisms to HER2-targeting treatment in HER2-positive gastric cancer (2015) (0)
- PO-0761 PROGNOSTIC FACTORS FOR PATIENTS WITH LEPTOMENINGEAL METASTASES FROM SOLID TUMOR (2012) (0)
- Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). (2023) (0)
- 5151 Trastuzumab mediated cardiac dysfunction outside clinical trials: a single center experience in Asia (2009) (0)
- 288 A phase 1 study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors (2020) (0)
- Biomarker-oriented study of durvalumab in combination with olaparib and paclitaxel in gastric cancer: A phase 2 trial-in-progress. (2021) (0)
- Abstract 2110: WEE1 inhibition could reverse trastuzumab resistance by downregulation of PD-L1 in HER2-positive cancers (2019) (0)
- Multicenter phase II trial of S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable colorectal cancer (2008) (0)
- 1500PA RANDOMIZED, MULTI-CENTER, PARALLEL-GROUP, PHASE II(SINGLE BLIND)/III(DOUBLE BLIND) STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GREEN CROSS PEGTEOGRASTIM (GCPGC) ON CHEMOTHERAPY-INDUCED NEUTROPENIA COMPARED TO PEGFILGRASTIM. (2014) (0)
- 6024 Does chemotherapy intensity in pre-operative chemoradiation for rectal cancer affect pathologic response? (2009) (0)
- Abstract P1-02-05: Prognostic role of PIK3CA mutational status in circulating tumor DNA (ctDNA) from HER2-positive metastatic breast cancer patients (2017) (0)
- Abstract 306: Antitumor effect of Wee1 inhibitor in gastric cancer cells (2017) (0)
- Prognostic Role of Body Mass Index in Advanced Small Bowel Adenocarcinoma Patients Receiving Palliative Chemotherapy (2016) (0)
- Abstract C121: A non-randomized, open-label, single-arm, phase 2 study of LY2875358 in Asian patients with MET diagnostic positive, advanced gastric cancer (2015) (0)
- 5055 POSTER The Palliative CMF is a Reasonable Salvage Treatment Option in Heavily Pretreated Patients With Metastatic Breast Cancer (2011) (0)
- Prognostic implication of soluble programmed death-ligand 1 (sPDL1) and its dynamic changes during FOLFIRINOX chemotherapy in unresectable pancreatic cancer. (2018) (0)
- Erratum to: Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation (2012) (0)
- Impact of Radiation Dose in Postoperative Radiation Therapy After R1 Resection for Extrahepatic Bile Duct Cancer: Long Term Results From a Single Institution (2017) (0)
- Abstract LB-165: Antiproliferative effects of AZD6738 and the inhibition of DDR activity (2015) (0)
- 552 Characteristics of the tumor microenvironment in IDH1-mutated cholangiocarcinoma patients from ClarIDHy trial (2022) (0)
- 553 DKN-01 and tislelizumab as a second-line (2L) investigational therapy in advanced DKK1 high gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial (2022) (0)
- Abstract 3442: Olaparib increases antitumor effects on epigenetically RAD51C-deficient human cancer cells. (2013) (0)
- Abstract P1-09-04: Proliferation and p21 refine risk of relapse in residual disease after HER2-directed therapies (2017) (0)
- Outcome Analysis of Adjuvant Chemoradiation after Incomplete Resection for Pancreatic Adenocarcinoma (2011) (0)
- Outcomes by antibiotic use in participants with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study. (2023) (0)
- Adjuvant Treatment for Gastric Cancer (2019) (0)
- 2844 Patterns of neck recurrence after postoperative radiotherapy of tonsillar cancer: Analysis of Korean radiation oncology group 11-07 data (2015) (0)
- A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03) (2022) (0)
- The analysis of T cell subsets and clinical efficacy of immune checkpoint blockades in patients with advanced gastric cancer using multiplex immunohistochemistry (2019) (0)
- EP-0983 PROGNOSTIC SIGNIFICANCE OF INNER QUADRANT INVOLVEMENT TREATED WITH MASTECTOMY AFTER NEOADJUVANT CHEMOTHERAPY (2012) (0)
- 754P Ibrutinib (Ibr) in combination with paclitaxel (Pac) has activity in patients (Pts) with advanced urothelial carcinoma (aUC): Final analysis of a phase Ib/II study (2020) (0)
- Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study (2023) (0)
- Does Chemotherapy Intensity in Pre-operative Chemoradiation for Rectal Cancer affect Pathologic Response? (2009) (0)
- Novel biomarker panel for the early detection of pancreatic cancer in the blood (2015) (0)
- Role of Adjuvant Chemoradiotherapy in Perihilar Bile Duct Cancer: A Single Institutional Long-Term Follow Up Analysis. (2021) (0)
- 6581 POSTER Phase II Study of RAD001 Monotherapy in Patients With Non-functioning Carcinoid or Pheochromocytoma/Paraganglioma (2011) (0)
- Abstract P3-11-13: Change of Ki-67 after long course of neoadjuvant chemotherapy as prognostic factors in patients with stage II, III triple negative breast cancer (2015) (0)
- Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses (2016) (0)
- 1097 Genetic polymorphisms of thymidylate synthase and DNA repair genes are associated with the toxicities of S-1 and cisplatin combination chemotherapy in metastatic or relapsed biliary tract cancer (2009) (0)
- The role of palliative resection in metastatic colorectal cancer: 10 years of experiences from a single institute. (2012) (0)
- Abstract 5479: Antitumor effect of KX-01, a novel Src and tubulin inhibitor, in triple negative breast cancer cells (2014) (0)
- Abstract PD09-05: Single nucleotide polymorphism of XRCC1 which participates in DNA repair mechanism predicts clinical outcome in relapsed or metastatic breast cancer patients treated with S1 and oxaliplatin chemotherapy: Results from multicenter prospective study (TORCH_KCSG BR07-03) (2012) (0)
- Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells (2015) (0)
- Adjuvant treatment patterns and clinical outcomes in patients with curative resected ampulla of Vater cancer. (2015) (0)
- Outcome Analysis of Chemoradiation in Unresectable Pancreatic Cancer Focusing on Treatment Sequencing Strategy. (2016) (0)
- A phase II biomarker-oriented study to evaluate paclitaxel, olaparib, and durvalumab combination in patients with advanced gastric cancer. (2023) (0)
- New evidences of chemotherapy in biliary tract cancer (2019) (0)
- EP-1182 Selective neck irradiation for oropharynx cancer in relation with human papilloma virus status (2019) (0)
- Abstract 1912: Jab1/Csn5 as a novel driver for therapeutic resistance in HER2-positive breast cancer (2012) (0)
- Phase II study of neoadjuvant chemotherapy with paclitaxel and cisplatin in Stage IIIA N2 non-small cell lung cancer. (2004) (0)
- Abstract CT096: Phase 1 study of RO7119929 (TLR7 agonist prodrug) in patients (pts) with advanced primary or metastatic liver cancers (2023) (0)
- Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma (2015) (0)
- Effect of combined consideration of distinct signatures of VEGF and soluble VEGFR2 on prognostic implication in gastric cancer. (2016) (0)
- Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment. (2023) (0)
- Abstract P4-13-19: Poziotinib, an oral, irreversible pan-HER inhibitor, demonstrates promising clinical activity in metastatic HER2 positive breast cancer patients (2016) (0)
- AB055. P-23. The impact of perioperative CA19-9 change on the survival and recurrence patterns after adjuvant chemoradiotherapy in extrahepatic cholangiocarcinoma (2019) (0)
- Identifying mechanisms of acquired immune escape from sequential, paired biopsies. (2022) (0)
- Evaluation of the willingness to pay for anticancer treatment among Korean patients with metastatic breast cancer: A multicenter, cross-sectional study. (2010) (0)
- Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX (2015) (0)
- Systemic Treatment of the Gastrointestinal Stromal Tumor (GIST) (2003) (0)
- HALO 110-101: Phase Ib study of PEGPH20 in combination with cisplatin + gemcitabine (PEGCISGEM) or atezolizumab (ATEZO) + CIS + GEM (PEGCISGEMATEZO) in patients with locally advanced/metastatic cholangiocarcinoma and gallbladder cancer. (2018) (0)
- Abstract 2081: Evaluation of Src as a therapeutic target in biliary tract cancer using bosutinib, a c-Src/Abl kinase inhibitor. (2013) (0)
- A Phase 2 Study of Futibatinib (TAS-120) in Patients with Myeloid or Lymphoid Neoplasms Harboring Fibroblast Growth Factor Receptor (FGFR) 1 Rearrangements (2021) (0)
- A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma (2018) (0)
- The Influence of the Treatment Response on the Impact of Resection Margin Status After Preoperative Chemoradiation Therapy in Rectal Cancer (2013) (0)
- P3-14-03: ABCB1 Single Nucleotide Polymorphismas a Possible Prognostic Factor in Breast Cancer Patients Receiving Docetaxel and Doxorubicin Neoadjuvant Chemotherapy on Systemic Treatment. (2011) (0)
- EP-1120: Treatment patterns and outcomes of cN0 nasopharynx cancer: Multiinstitutional study (2014) (0)
- P-601 High dose radiation therapy with 3 Gy per fraction in medicallyinoperable high dose radiation therapy with 3 Gy per fraction in medically inoperable stage I/II non-small cell lung cancer (2005) (0)
- Discrepancies of the Values on the Withholding Futile Interventions between Physician and Family Members of Terminal Cancer Patients. (2001) (0)
- 394 POSTER Hydroxamate histone deacetylase inhibitor selectively degrades Aurora A via HDAC6/Hsp90 pathway (2006) (0)
- Association of reduction of tumor metabolism with prognosis of advanced gastric cancer patients treated with palliative chemotherapy: Prospective cohort study. (2016) (0)
- Abstract 2386: Amphiregulin confers trastuzumab resistance by activating PI3K/Akt pathway in HER2-positive breast cancer. (2013) (0)
- 3048 The clinical implication of oral mucositis in solid tumor patients receiving conventional chemotherapy: as a bio-indicator for suffering adverse events and poor quality of life (2009) (0)
- A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors (2021) (0)
- Abstract CT149: BOLD-100-001 (TRIO039): a phase 1b/2a dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pre-treated advanced colorectal cancer: interim efficacy, safety and tolerability analysis (2023) (0)
- Kaplan-Meier analyses of (A) relapse free and (B) overall survival according to triple negative and (2011) (0)
- Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA). (2023) (0)
- P3-14-30: Concurrent Celecoxib with FEC Followed by Docetaxel Shows Good Responses and Prognosis in a Neoadjuvant Breast Cancer Study. (2011) (0)
- Methylations of NEUROG1, p16, and MLH1 and recurrence following adjuvant FOLFOX in colorectal cancer. (2012) (0)
- Abstract P5-15-01: Lamivudine Prophylaxis during Adjuvant Chemotherapy in Breast Cancer Patients with Hepatitis B Surface Antigen (2010) (0)
- Change of skeletal muscle index during the chemotherapy as a prognostic factor of survival in pancreatic cancer patients receiving palliative chemotherapy. (2015) (0)
- Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. (2023) (0)
- MO20-2 Phase I study of BI 754091 plus BI 754111 in Asian patients with gastric/gastroesophageal junction or esophageal cancer (2021) (0)
- Phase II study of evofosfamide (TH-302) monotherapy as a second-line treatment in advanced biliary tract cancer. (2018) (0)
- Abstract C266: Evaluation of Src as a therapeutic target in biliary tract cancer. (2013) (0)
- Multidisciplinary Oncologic Management for Recurrent Biliary Cancer after Surgical Resection (2014) (0)
- AB046. P-14. TREETOPP: a phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs) (2019) (0)
- ' s response to reviews Title : Diagnostic performance of contrast enhanced CT and 18 F-FDG PET / CT in suspicious recurrence of biliary tract cancer after curative resectionsection (2011) (0)
- Recent Progress in Immunotherapy for Gastric Cancer (2023) (0)
- High expression of MMP-9 is associated with better prognosis in extrahepatic bile duct cancer. (2017) (0)
- Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. (2012) (0)
- 5032 POSTER Clinical Outcome of Central Nervous System Metastases From Breast Cancer: Differences in Survival Depending on Systemic Treatment (2011) (0)
- IS2. Breast Cancer (2012) (0)
- 5087 New isolated mediastinal lymph node or pulmonary nodule during surveillance of breast cancer: clinical factors to differentiate metastasis from benign lesion (2009) (0)
- Abstract 2342: RO7119929, a TLR7 agonist prodrug, induces local inflammation of the tumor microenvironment (TME) by reprogramming myeloid cells in patients (pts) with advanced primary or metastatic liver cancers (2023) (0)
- Trastuzumab-mediated cardiac dysfunction (CDx) outside of clinical trials: Single Asian center experience. (2009) (0)
- A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma (2014) (0)
- P-699 Surgery with or without postoperative radiation therapy in patients with chest wall invading T3N0 non-small cell lung cancer (2005) (0)
- A Phase II Open Label Trial of PF-00299804 Monotherapy in Patients with HER-2 Positive Advanced Gastric Cancer After Failure of at Least one Prior Chemotherapy Regimen (2012) (0)
- O1-8-4PHASE 2 TRIAL OF GEMCITABINE PLUS UFT IN OXALIPLATIN, IRINOTECAN AND FLUOROPYRIMIDINE-REFRACTORY COLORECTAL CANCER (2014) (0)
- Inhibition of gastric cancer by a new controlled releasing compound of TLR-7/8 agonist via immune activation in a gastric cancer xenograft mice model. (2023) (0)
- Abstract 2073: Co-Targeting PARP and ATR in biliary tract cancer (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Do-youn Dy Oh?
Do-youn Dy Oh is affiliated with the following schools:
